secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0000886744-26-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron guides 2026 RYTELO revenue $220-240M; OPEX $230-240M
----------------------------------------------------------

- 2026 RYTELO net product revenue expected $220-240M.
- 2026 total operating expenses expected $230-240M.
- Amended Pharmakon term loan: Tranche B ($75M) and Tranche C ($50M) draw deadlines extended to July 30, 2026.
- Implemented strategic restructuring to streamline operations and support RYTELO commercial growth.
- Presented new IMerge trial analyses at ASH 2025 reinforcing RYTELO differentiation in LR-MDS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000088674426000003/0000886744-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000088674426000003/gern-20260112.htm
  HTML page:      https://secwatch.observer/filing/0000886744-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer